Skip to content

Person-checked company records fromPerson-checked records $750See a worked exampleHuman review in progress

Talk to sales

KeptIndex

Humanigen, Inc.

Initiate the GvHD study with the IMPACT Group

Not delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced
11 Jan 2021
Due
31 Dec 2021
Checked
25 Oct 2026
  • Deadline
  • Met
  • Late
  • Not met
  • Today

What the company said

“Initiate GvHD study with IMPACT Group”

What we found

Evidence strength A What the grades mean

The company did not initiate the RATinG study with the IMPACT Group in 2021; filings from 2022 and 2023 indicate the study was still in planning or early stages well after the deadline.

  • A
    Humanigen, Inc. 10-Q filed 2022-11-14 Regulatory filing · published 14 Nov 2022 · retrieved 25 Oct 2026 · kept permanently by the SEC · fingerprint ada6f4c1312e
    “We are currently evaluating lenzilumab for the early treatment of aGvHD in patients undergoing bone marrow transplants in a Phase 2/3 potentially registrational trial, known as the “RATinG” study.” ✓ confirmed on the page
  • A
    Humanigen, Inc. 10-K filed 2023-03-30 Regulatory filing · published 30 Mar 2023 · retrieved 25 Oct 2026 · kept permanently by the SEC · fingerprint a84bac09ce5d
    “We anticipate the first patient dosing in this study to occur in the second quarter of 2023 .” ✓ confirmed on the page

Checked 25 Oct 2026.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type
Clinical milestone
Indicative materiality
Medium rules
Action
Initiate
Deliverable
GvHD study
In the company’s control
Medium
Specificity
High
Depends on
Partner

How this entry was checked

  1. Commitment recordedThe company's words were matched word for word against the filing.
  2. First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
  3. Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
  4. Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Humanigen, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2021-C293310-021680 · Corrections policy

The Deadline Report

One email a week: the corporate commitments that came due, which were met, which slipped, and what is due next. Free. Stop any time.

No advertising. We never sell or share your address.